Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: TobaccoMan who wrote (7038)	1/25/1999 3:32:00 PM
From: Vic	Read Replies (1) \| Respond to of 43080

A while back I talked an analyst with a major brokerage firm and he told me that before they start following POSSIS, they're looking for the price to break $10 and for the company to obtain FDA approval on AngioJet. In the meantime, they are keeping a close eye on the company. I also read comments from another analyst who is saying they're projections for POSSIS are 100% increase in revenues for the next four quarters. The '98 annual report Possis shows "Potential Units" for A/J. a) 500,000 Cerebeal (Arterial) b) 2,000 Cerebeal (Venous) c) 1,000 Cervical Carotid d) 200,000 Lung e) 550,000 Coronary f) 190,000 AV Access g) 220,000 Leg & Graft h) 900,000 Deep Vein ----------- 2,563,000 "Potential Units" x $1,000 = $2,563,000,000. $2.5 billion Per Year in cash flow. Those projections would seem realistic when you look at the 30-day results from their randomized trial comparing use of the AngioJet to drug therapy. Quoting from the company's 1999 first quarter report: "...comparing use of the AngioJet System to the drug urokinase, demonstrated that the AngioJet System can: - reduce the average time to remove blood clot from 806 minutes to 2 minutes; - reduce the average hospital stay by nearly one day; - reduce the average intensive care unit stay by more than one day; - reduce bleeding complications from 13 to 3 percent; and - save hospitals an average of more then $3,500 per patient." One of the problems I see is that unlike drug therapy, which can be administered by any physician on duty in the emergency room, the AngioJet requires trained specialists. At present there are only a limited number of specialists qualified to perform this procedure. Unless that number is expanded, revenues from it will be equally limited. Of course, one would assume that presented with the data, hospitals will make the necessary commitment to ensure that qualified specialists and equipment are available. Of course, that's why we have bears and bulls, right????

To: TobaccoMan who wrote (7038)	1/25/1999 7:25:00 PM
From: AlienTech	Read Replies (2) \| Respond to of 43080

>>Since we are discussing chart patterns, have you run across any charts which would give me a good example of a Bear Trap or Bull Trap and the vol. significance for both?<< Hey I want to know the answer to that as well. From my personal experience recently, A bear trap was when I sold PSIX @ 28 on friday only to see it go to 37 on tuesday. A bull trap was when I bought it on tuesday only to see it go down to 28 on wednesday. So whats the moral of the story? Well glad you asked, Its stay outa the traps if you aint wearing some steel tipped toed boots.